Boston Scientific Corp.

  • Two Medical Equipment Companies to Own and One to Sell

    By Phillip Woolgar - August 13, 2013 | Tickers: BAX, BSX, MDT

    Most investors agree that the economy is recovering nicely, as evidenced by a 7.4% unemployment rate, down after hitting highs of over 10% in 2009. This means a major turnaround for earnings at a number of companies. The story is even brighter for medical equipment firms, which also look to capitalize on other factors.

    Investors in medical equipment companies should be excited about the massive number of babies born more »

  • This Medical Device Maker Seems to Be Quite Expensive

    By Anh HOANG - July 29, 2013 | Tickers: BSX, MDT, STJ

    Since the beginning of the year, Boston Scientific (NYSE: BSX) has enjoyed a great rally, climbing from $5.90 per share to nearly $11 per share. Its year-to-date return is nearly 91%, much higher than the S&P 500’s return of only 18.60%. In the first quarter, while Joel Greenblatt and Paul Tudor Jones reduced their positions in this company, Leon Cooperman and Jim Simons increased their exposure more »

  • Is This the Market's Last Remaining Bargain?

    By Ted Cooper - July 23, 2013 | Tickers: BSX, MDT, STJ

    It is hard to remember a time when the market was as overheated as it is today; even during the tech bubble, there were non-tech stocks that were cheap. Today, few stocks in any sector are even worth a closer look based on earnings multiples.

    However, one company -- Medtronic (NYSE: MDT) -- may be the last remaining bargain in this bull market. Medtronic sells at a steep discount to its peers more »

  • The Race In Medical Device Industry: Who Is The Winner?

    By usman iftikhar - July 18, 2013 | Tickers: BSX, LMAT

    LeMaitre Vascular (NASDAQ: LMAT), a global provider of disposable and implantable vascular devices, recently made an acquisition of privately-owned Clinical Instruments. The company also made three product launches from March 2013 to June 2013. Likewise, Boston Scientific Group (NYSE: BSX) acquired the assets of C.R. Bard and launched a whole new series of devices. This article analyzes these acquisitions, product launches and the future impact of these events on more »

  • Is Now the Time to Buy Medical Device Makers?

    By Jason Hall - July 18, 2013 | Tickers: BSX, MAKO, MDT, STJ, SYK

    As of this writing, the S&P 500 is up over 17% this year, while many of the biggest names in medical devices have run even farther. If we go back to last June 28 -- when the US Supreme Court ruled in favor of Obamacare and its 2.3% excise tax on medical device makers' gross revenues, medical device stocks have run even higher. Motley Fool Contributor Dan Caplinger described more »

  • This Momentum Play Might Make You Money

    By Dan Moskowitz - July 15, 2013 | Tickers: BSX, MDT, STJ

    Boston Scientific (NYSE: BSX) isn't the most popular stock on Wall Street. In fact, many investors don't want to have anything to do with it. It would be difficult to blame those investors, considering the company has seen revenue declines for three consecutive years and reported losses in four of the last five. The company’s recent performance hasn't been much better, reporting losses in three of more »

  • Hedge Fund Manager Ron Gutfleish’s Top Stock Picks

    By Meena Krishnamsetty - July 14, 2013 | Tickers: AGO, BSX, LMT, MBI, RRD

    We track quarterly 13F filings from hundreds of hedge funds, including Ron Gutfleish’s Elm Ridge Capital. We have found that these filings can be useful sources of investment strategies (for example, we have found that the most popular small cap stocks among hedge funds earn an average excess return of 18 percentage points per year) and we also think that it’s possible that investors might use them to more »

  • Does the Decline in Health Care Spending Spell Trouble for These Companies?

    By Madhukar Dubey - July 9, 2013 | Tickers: BSX, STJ, ZMH

    Over the last few years the global healthcare industry has witnessed significant growth with most countries spending enormously on healthcare. The expenditure on health care varies widely; the U.S. spends the most, at approximately $8,500 per person in 2012.

    However, the outlook beyond 2013 looks hazy. Industry experts believe there could be a possible expenditure reduction of as much as $400 billion in the next three years by more »

  • Is This Stock in Your Portfolio? If Not, Then Consider Getting Some

    By Harsh Chauhan - July 2, 2013 | Tickers: BSX, MDT, STJ

    The market gives investors a good number of chances to buy stocks when they are beaten down, and one such opportunity presented itself when medical devices maker Medtronic (NYSE: MDT) slipped in February this year. There were concerns about the company’s business slowing down, but its fourth-quarter results, which were released in May, put such doubts to rest.

    Medtronic’s huge size and diversification have helped the company overcome more »

  • Capitalizing on the Medical Trends of Tomorrow

    By Ryan Guenette - June 10, 2013 | Tickers: BSX, ISRG, MAKO, SYK, TFX

    A leader in the medical device industry, Intuitive Surgical Incorporated(NASDAQ: ISRG) has been trounced year to date by the Dow Jones Industrial Average, rising only 2.00% compared to the 16.41% return offered by the blue chip average.   

    Intuitive Surgical designs, manufacturers, and markets da Vinci Surgical Systems and related instruments and accessories. Based on market capitalization, the company is valued at $20.09 billion. Fundamentally, the more »

  • Don’t Believe the Hype about Medical Device Stocks

    By Jonathan Yates - June 9, 2013 | Tickers: BAX, BDX, BSX

    A major loser in the Affordable Health Care Act, or Obamacare, was supposed to be the medical device and equipment industry, which ranges from blue chip heavyweights with wide product offerings such as Boston Scientific (NYSE: BSX), Becton,Dickinson & Co. (NYSE: BDX), and Baxter International (NYSE: BAX) to specialized small caps such as PLC Systems (NASDAQ: PLCSF). The main feature of Obamacare that was expected to damage the sector the more »

  • Recent Aortic Valve Events that You Should Understand

    By Cory Renauer - June 3, 2013 | Tickers: BSX, EW, MDT

    Aortic stenosis is a type of heart disease involving a narrowing of the valve between the left ventricle of the heart and the aorta, or the aortic valve. According to the American Heart Association, about 0.4% of Americans have aortic stenosis, and the frequency of cases increases with age. About 2.8% of Americans aged 75 and older have moderate to severe aortic stenosis. Of those with severe symptoms more »

  • Hedge Fund North Run Capital’s Top Q1 Stock Picks

    By Meena Krishnamsetty - May 28, 2013 | Tickers: AET, BSX, GM, HNT, HSP

    North Run Capital, run by its founders Todd Hammer and Thomas Ellis, recently filed its Q1 13F with the SEC, which describes some of their top equity holdings; we’ll look at the top five. See the original 13F here, and it’s important to note that quantitative analyses have revealed that individual investors can benefit by paying attention to hedge fund activity; discover the secrets of this strategy.

    Let more »

  • What Are Insiders Buying These Days?

    By Meena Krishnamsetty - May 23, 2013 | Tickers: BBT, BSX, IBKC, X, WSR

    Studies show that stocks bought by insiders narrowly outperform the market (read our analysis of studies on insider trading) with our explanation for this finding being that company insiders have to be more confident than usual to buy the stock rather than diversify their wealth. Because the effect is not enormously large, as well as because of the fact that there are too many insider purchases for an investor to more »

  • Insiders Are Buying These Stocks Now

    By Meena Krishnamsetty - May 20, 2013 | Tickers: BSX, CCC, ETFC, MUR, TSN

    We maintain a database of insider trading activity in order to track insider purchases. In theory, insiders should be very reluctant to purchase additional shares of their company and therefore increase company-specific risk; they should instead prefer to diversify their wealth unless they are particularly confident that the stock offers high expected returns. Therefore, observing an insider purchase should serve as a signal of that level of confidence, and in more »

  • Bright Outlook for Device Makers

    By Ted Cooper - April 28, 2013 | Tickers: BSX, MDT, STJ | Editor's Choice

    In my last article, I argued that Medtronic (NYSE: MDT), Boston Scientific (NYSE: BSX), and St. Jude Medical (NYSE: STJ) were potentially-attractive investments. However, I made a key assumption in the article that is undoubtedly false: I assumed that each company's operations will stay the exact same from now into eternity.

    Although the assumption is false, it is a useful starting point for further analysis. The goal of this more »

  • Obamacare Uncertainty Presents Opportunity

    By Ted Cooper - April 26, 2013 | Tickers: BSX, MDT, STJ

    Health care companies have been caught in a state of limbo since the passage of Obamacare. The market is still sorting out who wins and who loses from the landmark health care overhaul. Meanwhile, Congress has plans to repeal or amend parts of the law. All of this leads to uncertainty about these companies' futures. However, the market's indecisiveness poses as an opportunity for enterprising investors to scoop up more »

  • St. Jude Medical news raises investors’ heartbeat

    By Shas Dey - April 15, 2013 | Tickers: BSX, MDT, STJ

    Exciting news came out for St. Jude Medical (NYSE: STJ) shareholders as the company announced that its product, the AMPLATZER Cardiac Plug (ACP), was going into a key phase of clinical trial testing. The ACP is used for the prevention of stroke and the clinical trial is being conducted to demonstrate whether the ACP device is both able and safe to prevent blood clots from travelling out of the left more »

  • Buying the Boston Boom

    By Marshall Hargrave - April 14, 2013 | Tickers: ABT, BSX, MDT, STJ

    Boston Scientific (NYSE: BSX) has rallied nicely year to date, up over 35%, but is there still room to grow for this heart-related devices company? Cardiovascular disease remains the number one killer worldwide. The number of adults diagnosed with heart disease in the U.S. is around 11.8 percent of the total population. 
    Earlier this year Boston revised growth plans to better account for the challenging economic environment. Boston more »
  • Prem Watsa Is Buying Into This Small-Cap Stock, Should You Follow?

    By Anh HOANG - March 25, 2013 | Tickers: BSX, MDT, NVDQ

    Recently, Prem Watsa, who is well known as “Canada’s Warren Buffett”, increased his stake significantly in the Canadian medical imaging and therapeutic device company, Novadaq Technologies (NASDAQ: NVDQ). He first initiated a long position in the company in the fourth quarter of 2012, and then he added more in the middle of February, to own nearly 2.84 million shares in the company. Should we follow Prem Watsa into more »

  • Page 1 of 3